000 04267nam a22004455i 4500
001 vtls000557747
003 RU-ToGU
005 20210922085443.0
007 cr nn 008mamaa
008 170212s2015 gw | s |||| 0|eng d
020 _a9783319099156
_9978-3-319-09915-6
024 7 _a10.1007/978-3-319-09915-6
_2doi
035 _ato000557747
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC648-665.2
072 7 _aMJG
_2bicssc
072 7 _aMED027000
_2bisacsh
082 0 4 _a616.4
_223
245 1 0 _aLeptin
_helectronic resource
_bRegulation and Clinical Applications /
_cedited by Sam Dagogo-Jack, MD.
260 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2015.
300 _aXXIII, 287 p. 48 illus., 27 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aDiscovery of leptin and elucidation of leptin gene expression -- Leptin receptors and mechanism of action -- Leptin interaction with brain orexigenic and anorexigenic pathways -- Measurement of circulating leptin and soluble leptin receptors -- Physiological and hormonal factors that influence leptin production -- Leptin, obesity and leptin resistance -- Leptin and intermediary metabolism: Focus on glucoregulation and lipid metabolism -- Leptin in acute stress -- Leptin and the kidney -- Leptin, immune function, and inflammation -- Leptin and bone -- Leptin, cell cycle, and cancer -- Leptin, the autonomic nervous system, and hypertension -- Dynamic leptin secretion in obesity and diabetes -- Leptin therapy of congenital leptin deficiency -- Leptin therapy in people with normal leptin gene -- Leptin therapy in patients with lipodystrophy and syndromic insulin resistance -- Leptin therapy in women with hypothalamic amenorrhea -- Leptin therapy as a substitute for insulin replacement in experimental models of diabetes: Clinical implications in humans -- Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases.
520 _aTwenty years after its discovery, recombinant human leptin has been approved by the Food and Drug Administration for the treatment of patients with lipodystrophy. Beginning with a synthesis of the vast body of work on its discovery, dissection of mechanisms, and effects in experimental models , the focus of this book shifts to a consideration of the regulation and role of leptin in humans. The emphasis on human-level data is a unique feature of this book. The results of numerous studies indicate that leptin is indeed a regulated human hormone. Leptin provides a detailed account of the myriad physiological, hormonal, metabolic, immunological, mitogenic and inflammatory modulators and targets of leptin in a single volume. Next follows a comprehensive presentation of the therapeutic trials of recombinant leptin in patients with congenital leptin deficiency, lipodystrophy, hypothalamic amenorrhea, and other emerging areas, including leptin supplementation in leptin-replete subjects, leptin substitution for insulin in diabetic models, and novel combination regimens of leptin and other biogenic peptides. Unanswered questions and future directions in leptin research are highlighted in the Foreword by Dr. Jeffrey Friedman and throughout the volume. Identifying such questions helps direct research that could deepen understanding of the complex regulation of leptin under physiological and pathological conditions, a critical prerequisite to its rational deployment in the treatment of human disorders.
650 0 _amedicine.
_9566220
650 0 _aEndocrinology.
_9303589
650 0 _aMetabolic diseases.
_9566257
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aEndocrinology.
_9303589
650 2 4 _aMetabolic Diseases.
_9566258
700 1 _aDagogo-Jack, MD, Sam.
_eeditor.
_9463416
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-09915-6
912 _aZDB-2-SME
999 _c412673